TY - JOUR
T1 - Comparing csf amyloid-beta biomarker ratios for two automated immunoassays, elecsys and lumipulse, with amyloid pet status
AU - Willemse, Eline A. J.
AU - Tijms, Betty M.
AU - van Berckel, Bart N. M.
AU - le Bastard, Nathalie
AU - van der Flier, Wiesje M.
AU - Scheltens, Philip
AU - Teunissen, Charlotte E.
N1 - Funding Information: The authors thank Joop Nijhof, Kees van Uffelen, and Lynn Boonkamp for their excellent technical assistance. We are thankful for receiving in-kind contributions in the form of assay kits from Roche Diagnostics and Fujirebio Europe N.V. These contributions had no influence on the results or conclusions from this study. Part of this study was funded by a ZonMW Memorabel grant (project number 733050206). Research of Alzheimer Center Amsterdam is part of the neurode-generation research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The chair of Wiesje van der Flier is supported by the Pasman stichting. PET scan costs were funded by grants of ZonMW, Piramal Imaging (now Life-MI), GE Healthcare, Avid Radiopharmaceuticals, and the Center for Translational Molecular Medicine. Funding Information: The authors thank Joop Nijhof, Kees van Uffelen, and Lynn Boonkamp for their excellent technical assistance. We are thankful for receiving in-kind contributions in the form of assay kits from Roche Diagnos-tics and Fujirebio Europe N.V. These contributions had no influence on the results or conclusions from this study. Part of this study was funded by a ZonMW Memorabel grant (project number 733050206). Research of Alzheimer Center Amsterdam is part of the neurode-generation research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The chair of Wiesje van der Flier is supported by the Pasman stichting. PET scan costs were funded by grants of ZonMW, Piramal Imaging (now Life-MI), GE Healthcare, Avid Radiopharmaceuticals, and the Center for Translational Molecular Medicine. Publisher Copyright: © 2021 The Authors. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Introduction: We evaluated for two novel automated biomarker assays how cere-brospinal fluid (CSF) amyloid beta (Aβ)1– 42-ratios improved the concordance with amyloid positron emission tomography (PET) positivity compared to Aβ1– 42 alone. Methods: We selected 288 individuals from the Amsterdam Dementia Cohort across the Alzheimer’s disease clinical spectrum when they had both CSF and amyloid PET visual read available, regardless of diagnosis. CSF Aβ1– 42, phosphorylated tau (p-tau), and total tau (t-tau) were measured with Elecsys and Lumipulse assays, and Aβ1–40 with Lumipulse. CSF cut-points were defined using receiver operating characteristic (ROC) for amyloid PET positivity. Results: For both Elecsys and Lumipulse the p-tau/Aβ1– 42,Aβ1– 42/Aβ1– 40,andt-tau/Aβ1– 42 ratios showed similarly good concordance with amyloid PET (Elecsys: 93,90,90%; Lumipulse: 94,92,90%) and were higher than Aβ1– 42 alone (Elecsys 85%; Lumipulse 84%). Discussion: Biomarker ratios p-tau/Aβ1– 42,Aβ1– 42/Aβ1– 40,t-tau/Aβ1– 42 on two automated platforms show similar optimal concordance with amyloid PET in a memory clinic cohort.
AB - Introduction: We evaluated for two novel automated biomarker assays how cere-brospinal fluid (CSF) amyloid beta (Aβ)1– 42-ratios improved the concordance with amyloid positron emission tomography (PET) positivity compared to Aβ1– 42 alone. Methods: We selected 288 individuals from the Amsterdam Dementia Cohort across the Alzheimer’s disease clinical spectrum when they had both CSF and amyloid PET visual read available, regardless of diagnosis. CSF Aβ1– 42, phosphorylated tau (p-tau), and total tau (t-tau) were measured with Elecsys and Lumipulse assays, and Aβ1–40 with Lumipulse. CSF cut-points were defined using receiver operating characteristic (ROC) for amyloid PET positivity. Results: For both Elecsys and Lumipulse the p-tau/Aβ1– 42,Aβ1– 42/Aβ1– 40,andt-tau/Aβ1– 42 ratios showed similarly good concordance with amyloid PET (Elecsys: 93,90,90%; Lumipulse: 94,92,90%) and were higher than Aβ1– 42 alone (Elecsys 85%; Lumipulse 84%). Discussion: Biomarker ratios p-tau/Aβ1– 42,Aβ1– 42/Aβ1– 40,t-tau/Aβ1– 42 on two automated platforms show similar optimal concordance with amyloid PET in a memory clinic cohort.
KW - Alzheimer’s disease
KW - Amyloid positron emission tomography
KW - Amyloid-beta
KW - Biomarkers
KW - Cere-brospinal fluid
KW - Concordance cut-points
KW - Elecsys
KW - Lumipulse
UR - http://www.scopus.com/inward/record.url?scp=85106272227&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/dad2.12182
DO - https://doi.org/10.1002/dad2.12182
M3 - Article
C2 - 33969174
SN - 2352-8729
VL - 13
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12182
ER -